Skip to main content
Premium Trial:

Request an Annual Quote

BioReference Laboratories' OnkoSight

BioReference Laboratories has introduced two sequencing tests that it believes will enhance the information that physicians can obtain from tumor samples when treating oncology patients. The company will offer this next-generation sequencing program, called OnkoSight, through its GenPath Oncology business unit. The custom-designed NGS panels ar OnkoSight Solid, consisting of 31 genes for solid tumors; and OnkoSight Myeloid, comprising 37 genes for myeloid disorders. The company said that six additional focused panels are available based on tumor type: lung, colon, melanoma, myelodsyplastic syndromes, acute myeloid leukemia, and myeloproliferative neoplasms.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.